SCHEMBL7344916

SCHEMBL7344916

NN=Cc1ccc2cccc(NC(=O)CO)c2c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
LMNA P02545 2/20 0.41
POLB P06746 1/20 0.41
TRPV1 Q8NER1 4/20 0.40
TSHR P16473 2/20 0.40
ALDH1A1 P00352 2/20 0.40
USP2 O75604 1/20 0.40
KDM4E B2RXH2 2/20 0.40
GAA P10253 1/20 0.40
PPARG P37231 1/20 0.39
PLAU P00749 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
APOBEC3A P31941 1/20 0.38
HTT P42858 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7341347 0.89 MAPT (0.41) MAPTPOLBTRPV1ALDH1A1KDM4E
SCHEMBL7334058 0.85 TSHR (0.45) MAPTPOLBTSHRALDH1A1KDM4E
SCHEMBL7335604 0.85 KDM4E (0.58) MAPTLMNAPOLBTRPV1ALDH1A1
SCHEMBL7335335 0.85 TRPV1 (0.43) MAPTTRPV1KDM4EGAAPLAU
SCHEMBL28742394 0.84 KDM4E (0.51) MAPTPOLBTRPV1ALDH1A1KDM4E
SCHEMBL7336819 0.82 SMN1; SMN2 (0.44) MAPTPOLBTRPV1ALDH1A1KDM4E
Trifluoroacetic Acid SCHEMBL7343434 0.79 CYP1A2 (0.43) MAPTPOLBTRPV1ALDH1A1KDM4E
Trifluoroacetic Acid SCHEMBL7456126 0.79 TRPV1 (0.40) MAPTTRPV1KDM4EGAAPLAU
Trifluoroacetic Acid SCHEMBL7340772 0.77 KDM4E (0.44) MAPTPOLBTRPV1ALDH1A1KDM4E
Trifluoroacetic Acid SCHEMBL7337767 0.76 PLAU (0.43) POLBTRPV1ALDH1A1GAAPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 MAPT 3752/4885LMNA 1886/4885POLB 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.